EARLY IFNb-1a and Atorvastatin Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis

Inclusion Criteria:

Patients with isolated clinical syndrome suggestive of MS

At least three out of four magnetic resonance imaging (MRI) findings on the initial scan:

One Gd-enhancing lesion or nine T2 hyperintense lesions;
At least one infratentorial lesion;
At least one juxtacortical lesion; and
At least three periventricular lesions.
Expanded Disability Status Scale (EDSS) 0-5.5
18 to 60 years of age
At least one relapse in previous 12 months

Exclusion Criteria:

Patients with a diagnosis of clinically definitive relapsing-remitting (RR) MS, secondary progressive, or primary progressive MS.
Patients who have ever been treated with mitoxantrone, cytoxan, cyclophosphamide, or total lymphoid irradiation (TLI).
Patients treated with IFNb-1a, IFNb-1b, glatiramer acetate, intravenous immunoglobulins (IVIg), plasma exchange, methotrexate, or azathioprine in the previous 3 months.
Patients treated with intravenous or oral steroids within 30 days prior to baseline MRI.
Patients who have been treated with statins in the previous 3 months.
Pregnant or breast-feeding women.
Patients with a history of severe cardiac, hepatic, pulmonary, gastrointestinal, or renal disease.
Abnormal baseline blood tests including alanine transaminase (ALT) or aspartate transaminase (AST) greater than twice the upper limit of normal